trimethyloxamine has been researched along with Brain Dead in 1 studies
trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure
trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robert, R | 1 |
| Guilhot, J | 1 |
| Pinsard, M | 1 |
| Longeard, PL | 1 |
| Jacob, JP | 1 |
| Gissot, V | 1 |
| Hauet, T | 1 |
| Seguin, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant[NCT04529005] | Phase 4 | 20 participants (Actual) | Interventional | 2020-08-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of vasopressor usage while in the operating room measured in hours of usage presented as median and IQR. (NCT04529005)
Timeframe: Duration of usage during the transplant surgery - presented in hours
| Intervention | hours (Median) |
|---|---|
| Angiotensin II (Giapreza) | 1 |
The presence of arrhythmia was confirmed via EKG, flowsheet, or note documentation from the electronic medical record. (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 1 |
The presence of Delayed Graft Function was captured for each patient and defined by the need for renal replacement therapy up to 7 days post-operative. (NCT04529005)
Timeframe: From post-op to 7 days post-op
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 2 |
The presence of post-operative fungal infections were captured prior to discharge as documented by the clinical care team in the electronic medical record. (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 0 |
The presence of hyperglycemia was captured for each patient and was determined by those patients requiring the use of an insulin infusion after their transplant surgery. (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 1 |
The presence of digital or other peripheral/visceral ischemia was captured from reviewing chart documentation for each patient. (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 0 |
Incidence of venous or arterial thrombosis occurring during the hospitalization for kidney transplant (captured by ultrasound or other diagnostic imaging) (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 0 |
1 other study available for trimethyloxamine and Brain Dead
| Article | Year |
|---|---|
A pair analysis of the delayed graft function in kidney recipient: the critical role of the donor.
Topics: Adolescent; Adult; Age Factors; Aged; Biomarkers; Brain Death; Child; Citric Acid; Delayed Graft Fun | 2010 |